We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00512538
Recruitment Status : Terminated (Interruption of business relations between Study Sponsor and Device Manufacturer)
First Posted : August 7, 2007
Last Update Posted : August 7, 2007
Information provided by:

August 3, 2007
August 7, 2007
August 7, 2007
October 2000
Not Provided
Time to complete wound healing (full epithelialization with no drainage) [ Time Frame: through 12 weeks ]
Same as current
No Changes Posted
Incidence of complete healing [ Time Frame: at 12 weeks ]
Same as current
Not Provided
Not Provided
Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers
A Randomized, Open-Label, Multi-Center Study to Compare the Safety and Efficacy of Apligraf Versus Standard Therapy (i.e., Saline Moistened Dressing Regimen) in the Treatment of Diabetic (Primarily Neuropathic) Foot Ulcers
The purpose of this study is to determine the ability of Apligraf to improve the time to and incidence of complete wound closure of diabetic foot ulcers, as compared to diabetic foot ulcers treated with standard therapy.

Ulceration of the diabetic foot is a result of multiple problems including repetitive stress on a neuropathic or insensate area that is often associated with an underlying bony prominence. By healing diabetic foot ulcers quickly the risks of infection, osteomyelitis (infeciton of the bone) and limb loss can be reduced.

This study will evaluate the ability of Apligraf to heal diabetic foot ulcers that have been present for at least 2 weeks and are between 1 - 16 cm2 in area. Patients will be randomized to either (50:50 chance) treatment with Apligraf or a saline moistened dressing regimen (standard therapy). All patients will receive standard cares for the ulcers which includes debridement, orthotics and off-loading throughout the treatment period.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Diabetic Foot
Device: Bi-layered cell therapy (Apligraf)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2002
Not Provided

Inclusion Criteria:

  • diabetic ulcer of primarily neuropathic origin on the plantar region of the forefoot
  • ulcer extending through the dermis but without sinus tract, tendon, capsule or bone exposure
  • ulcer present for at least 2 weeks and measuring 1- 16 cm2
  • diminished sensesation on target extremity/foot
  • ulcer is not infected
  • Type 1 or 2 diabetes with adequate glycemic control
  • Adequate vascular supply to the target extremity

Exclusion Criteria:

  • Charcot foot
  • Non-neuropathic ulcers
  • Skin cancer within or adjacent to the target ulcer
  • Osteomyelitis or an infected ulcer
  • Clinically significant medical condition that would impair wound healing
  • Females who are pregnant
  • Received within 4 weeks of study entry systemic corticosteriods, immunosuppresive agents, radiation therapy or chemotherapy
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
CGS0769 B304
Not Provided
Not Provided
Not Provided
Not Provided
Principal Investigator: Michael E Edmonds, MD Diabetic Foot Clinic, Kings College Hospital, London UK
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP